查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2001082

老龄化黄斑部病变市场：2026-2032年全球市场预测（按疾病类型、治疗方法、基准视力、给药途径、分销管道和最终用户划分）

Age-related Macular Degeneration Market by Disease Type, Treatment Modality, Baseline Visual Acuity, Route of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年，与老龄化的黄斑部病变市场价值为 115.9 亿美元，预计到 2025 年将增长至 124.9 亿美元，复合年增长率为 8.10%，到 2032 年将达到 216.3 亿美元。

主要市场统计数据
基准年 2024 115.9亿美元
预计年份：2025年 124.9亿美元
预测年份 2032 216.3亿美元
复合年增长率 (%) 8.10%

简要概述当前临床、技术和营运趋势如何重塑老龄化黄斑部病变的治疗和策略重点。

老龄化黄斑部病变（ AMD）仍然是眼科研究和临床治疗的核心挑战，其主要驱动因素是人口结构变化和治疗方法的进步。治疗手段已不再局限于单一治疗方法，而是扩展到生物製药、缓释装置、基因疗法和先进影像技术，这给临床医生、保险公司和製造商带来了复杂的挑战。随着诊断准确性的提高和患者照护的日益整合，相关人员必须在门诊、医院和专科医疗中心层级协调临床需求与实际运作。

治疗方法、诊断技术和数位化护理路径的创新如何重新定义临床实务、经营模式和竞争优势？

老龄化黄斑部病变的治疗方法和技术进步正在从根本上重塑临床路径和供应商策略。曾经是新生血管疾病治疗标准疗法的抗血管内皮生长因子（VEGF）药物，如今与缓释植入、可更换给药平台以及旨在减轻治疗负担和提高治疗可持续性的新型基因治疗方法并存。包括高解析度光学同调断层扫描（OCT）和整合多模态诊断在内的成像技术的进步，正在促进疾病分层并实现早期疗育。

评估 2025 年美国关税上调对眼科医疗保健供应链、采购实务和策略製造决策的影响。

美国2025年实施的关税上调对眼科医疗保健的供应链和服务交付产生了连锁的营运和策略影响。进口零件、医疗设备和某些生物原料关税的提高，增加了依赖国际製造地生产管瓶、预填充式注射器、给药系统和专用设备的供应商的接收成本。为此，製造商重新审视了其筹资策略，加快了供应商多元化，并优先考虑认证其他契约製造组织（CMO），以降低单一国家成本衝击的风险。

将治疗领域、给药途径、医疗保健环境和分销管道与临床导入状态和策略机会联繫起来的基于细分的综合洞察。

市场细分为解读不同治疗领域和通路的临床导入模式和商业性机会提供了一个框架。基于治疗方法，市场分析区分了非药物疗法和药物干预，其中非药理学的处置方法进一步细分为雷射疗法和动态疗法。这种结构突显了微创治疗方案和药物疗法的交叉领域。按药物类别划分，分析观点区分了抗VEGF药物和皮质类固醇，并将抗VEGF药物进一步细分为阿柏西普、Bevacizumab、布罗卢西珠单抗和雷珠单抗，同时将皮质类固醇分为地塞米松和曲安奈德，从而清晰地展现了基于适应症的治疗方法选择、处方集趋势和使用情况。

美洲、欧洲、中东和非洲以及亚太地区临床引入、监管途径和商业化方法的区域差异。

区域趋势持续影响美洲、欧洲、中东和非洲以及亚太地区的临床实践模式、监管预期和商业化策略。在美洲，完善的健保报销体系和玻璃体内注射疗法的高普及率凸显了治疗优化、用药依从性策略以及减少就诊次数的创新的重要性。医疗整合和一体化医疗网络也影响采购和合约行为。在欧洲、中东和非洲，不同的监管管道和支付模式要求製药公司开发针对特定区域的证据和适应性定价策略，以确保产品被纳入医保覆盖范围并维持盈利。

在老龄化黄斑部病变(AMD) 生态系统中，塑造治疗领导地位、交付创新和综合解决方案的公司的策略行动和伙伴关係模式

在老龄化黄斑部病变(AMD) 生态系统中，企业策略的特征是产品组合多元化、建立目标明确的伙伴关係，以及投资于先进的製造流程和资料能力。成熟的生物製药公司透过不断改进已通过核准的抗 VEGF 药物，并支持真实世界数据研究，从而保持其领先地位，这些研究为拓展适应症和创新给药方法奠定了基础。同时，在缓释系统和眼科器械领域拥有独特优势的公司，正利用策略联盟，将给药平台与成熟的生物製药结合，打造差异化的产品和服务，以满足临床医生和患者减轻治疗负担的需求。

高阶主管应采取切实可行的、优先考虑的策略行动，以提高临床价值、供应弹性、市场进入和商业性差异化。

产业领导企业应采取一系列切实可行的措施，以协调临床价值、商业性永续性和营运韧性。首先，他们应优先开发缓释机制和联合治疗，以显着降低治疗频率，同时维持并改善长期视觉功能。证据包应强调以病人为中心的终点指标和医疗系统资源的利用。其次，他们应透过在全球范围内认证多家生产合作伙伴，并投资于库存分析，以降低前置作业时间风险并控制营运资金需求，从而增强供应链的柔软性。

一个稳健的混合方法研究框架，整合了对关键相关人员的访谈、二手监管和临床证据以及情境检验，以获得可操作的见解。

本研究途径结合了初步研究和对二手资料的全面回顾，以确保研究结果的可靠性和实用性。初步研究包括对眼科医生、医院和专科医疗中心的采购经理、销售部门的高级管理人员以及临床试验的主要研究者进行结构化访谈，以了解他们对治疗方案引入、运营限制以及与支付方互动等方面的第一手观点。二级资讯来源包括同行评审的临床文献、监管核准文件、临床试验註册资讯和公开文件，以检验治疗方案、适应症和安全性数据。

全面概述了临床创新、营运准备和策略挑战，这些因素对于改善老龄化黄斑部病变。

简而言之，老龄化黄斑部病变（AMD）的治疗格局正处于一个转折点，治疗创新、给药技术和机构压力在此交汇，重塑着治疗模式。减少治疗频率并满足黄斑部病变未满足需求的进展老龄化巨大的临床前景，但其实现需要协作式证据生成、灵活的商业模式和稳健的供应链。积极调整采购惯例、投资于生产灵活性并将证据策略与支付方期望一致的相关人员，将更有能力将科学突破转化为永续的临床和商业性价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章老龄化黄斑部病变市场：依疾病类型划分

  • 湿性AMD
  • 干性酸性矿山排水

第九章：依治疗方法老龄化黄斑部病变市场

  • 药物治疗
    • 抗 VEGF 药物
      • 阿柏西普
      • 雷尼珠单抗
      • Bevacizumab
      • 布罗卢西珠单抗
    • 补体抑制剂
      • 佩格塞塔科计划
      • 阿巴辛卡普塔德·佩戈尔
    • 蛋白酪氨酸激酶抑制剂
    • 整合素抑制剂
    • 营养补充品
  • 基因治疗
  • 动态疗法
  • 放射线治疗
  • 视觉復健和辅助器具

第十章基准视力分類的老龄化黄斑部病变市场

  • 20/40 或以上
  • 20/50～20/200
  • 少于 20/200

第十一章老龄化黄斑部病变市场：依给药途径划分

  • 玻璃体内注射
  • 口服
  • 眼药水

第十二章老龄化黄斑部病变市场：依分销管道划分

  • 网路药房
  • 物理药房

第十三章老龄化黄斑部病变市场：依最终用户划分

  • 诊所
  • 医院
  • 专业眼科中心
  • 居家照护设施

第十四章老龄化黄斑部病变市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章老龄化黄斑部病变市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章老龄化黄斑部病变市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国老龄化黄斑部病变市场

第十八章：中国老龄化黄斑部病变市场

第十九章 竞争情势

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • AbbVie Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Outlook Therapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz Group AG
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-F927BA46233D

The Age-related Macular Degeneration Market was valued at USD 11.59 billion in 2024 and is projected to grow to USD 12.49 billion in 2025, with a CAGR of 8.10%, reaching USD 21.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.59 billion
Estimated Year [2025] USD 12.49 billion
Forecast Year [2032] USD 21.63 billion
CAGR (%) 8.10%

A concise orientation to current clinical, technological, and operational forces reshaping age-related macular degeneration care and strategic priorities

Age-related macular degeneration remains a central focus for ophthalmic research and clinical care, driven by demographic shifts and evolving therapeutic possibilities. The landscape has expanded beyond single-modality treatments to encompass biologics, sustained-release devices, gene-based interventions, and advanced imaging, creating a complex environment for clinicians, payers, and manufacturers to navigate. As diagnostic precision improves and patient pathways become more integrated, stakeholders must reconcile clinical need with operational realities across outpatient clinics, hospitals, and specialty centers.

Translational advances in molecular biology and drug delivery have shortened development cycles for some therapeutic classes while introducing new regulatory and manufacturing challenges. Concurrently, payer scrutiny and procurement practices have intensified, prompting providers to optimize treatment regimens and care delivery models. For decision-makers, understanding the interplay between therapeutic innovation, clinical adoption, and supply chain resiliency is essential to formulate sustainable strategies that deliver improved visual outcomes while controlling total cost of care.

This executive summary synthesizes prevailing trends, supply chain dynamics, segmentation insights, regional nuances, and strategic imperatives to enable informed action. The intent is to offer an analytically rigorous yet accessible foundation for senior leaders seeking to prioritize investments, partnerships, and operational changes in the current era of rapid technological and policy-driven shifts.

How converging therapeutic innovations, diagnostics, and digital care pathways are redefining clinical practice, commercial models, and competitive advantage

The therapeutic and technological shifts occurring in age-related macular degeneration are reshaping clinical pathways and vendor strategies in meaningful ways. Anti-VEGF agents, which once defined the standard of care for neovascular disease, now coexist with sustained-release implants, refillable delivery platforms, and emerging gene-based modalities that aim to reduce treatment burden and improve durability. Imaging advances, including higher-resolution optical coherence tomography and integrated multimodal diagnostics, have enhanced disease stratification and enabled earlier interventions.

Artificial intelligence and cloud-enabled workflows are increasingly used to triage referrals, monitor progression remotely, and standardize treatment decision-making across networks. These capabilities are altering care delivery economics by shifting some monitoring activities to community clinics and telemedicine platforms while concentrating procedural interventions within specialty centers. The convergence of real-world evidence and adaptive regulatory pathways has accelerated the translation of innovative devices and biologics, but it has also amplified expectations for post-approval surveillance and outcome-based contracting.

As a result, commercial models are evolving to accommodate value-based arrangements, differentiated pricing for sustained-delivery products, and new partnerships between diagnostic vendors and therapeutic developers. The cumulative effect is a landscape in which clinical effectiveness, operational efficiency, and commercial agility collectively determine competitive positioning.

Assessment of how 2025 tariff escalations in the United States disrupted ophthalmic supply chains, procurement behavior, and strategic manufacturing decisions

The imposition of elevated tariff measures in the United States during 2025 has created a cascade of operational and strategic consequences for the ophthalmic supply chain and service delivery. Higher duties on imported components, devices, and certain biologic inputs elevated landed costs for suppliers who rely on international manufacturing hubs for vials, prefilled syringes, delivery systems, and specialized instrumentation. In response, manufacturers reassessed sourcing strategies, accelerated supplier diversification, and prioritized qualification of alternative contract manufacturing organizations to reduce exposure to single-country cost shocks.

Procurement teams within hospitals and specialty centers began to renegotiate long-term supply agreements and to demand greater price transparency from vendors, which intensified commercial pressure on manufacturers to absorb or offset tariff-related cost increases. Some providers explored changes in inventory management, such as larger safety stocks or staggered purchasing cycles, to buffer against short-term disruption, but these adjustments increased working capital requirements and warehousing needs. In parallel, payers scrutinized reimbursement pathways and utilization patterns more closely, seeking to align reimbursement with overall value and to limit the transference of tariff-induced cost inflation to final service pricing.

The tariff environment also catalyzed conversations about nearshoring and localized production capacity, particularly for high-volume consumables and delivery devices, where scale economics could justify capital investments. Regulatory interplay and lead times for establishing domestic manufacturing, however, constrained the speed at which reshoring could mitigate cost impacts. Consequently, companies that adopted flexible sourcing, hedging strategies, and stronger supplier governance demonstrated greater resilience, while those with concentrated upstream exposure experienced amplified margin pressure and operational strain.

Integrated segmentation-driven insights linking therapeutic classes, delivery pathways, care settings, and distribution channels to clinical adoption and strategic opportunity

Segmentation provides a framework to interpret clinical adoption patterns and commercial opportunity across distinct therapeutic and distribution pathways. Based on Treatment, market analysis differentiates Non-Pharmacological modalities and Pharmacological interventions, with Non-Pharmacological approaches further situated within Laser Therapy and Photodynamic Therapy; this structure highlights where minimally invasive procedural options intersect with drug-based approaches. Based on Drug Class, the analytical lens distinguishes Anti-VEGF agents from Corticosteroids, and further dissects Anti-VEGF into Aflibercept, Bevacizumab, Brolucizumab, and Ranibizumab while categorizing Corticosteroids into Dexamethasone and Triamcinolone, enabling a clear view of therapeutic substitution, formulary dynamics, and label-driven usage.

Based on Type, the segmentation separates Dry and Wet disease pathways to emphasize differences in disease progression, unmet need, and potential for regenerative or complement-targeted strategies. Based on End User, the analysis considers Clinics, Hospitals, and Specialty Ophthalmic Centers as distinct channels of care delivery, each with unique procurement, staffing, and capacity characteristics that shape technology adoption and treatment frequency. Based on Distribution Channel, the study assesses Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways to reflect evolving purchasing behaviors, the rise of digital dispensing models, and implications for cold-chain logistics and patient access.

Together, these segmentation dimensions allow for nuanced interpretation of clinical utilization patterns, capital and operating investment priorities, and the differential impact of policy or reimbursement changes across care settings. By mapping therapeutic innovations to end-user and distribution realities, stakeholders can better anticipate adoption bottlenecks and prioritize interventions that address the most consequential frictions.

Regional nuances in clinical adoption, regulatory pathways, and commercialization approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape clinical practice patterns, regulatory expectations, and commercialization strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established reimbursement systems and high adoption rates of intravitreal therapies have driven an emphasis on treatment optimization, adherence strategies, and innovations that reduce visit frequency; provider consolidation and integrated delivery networks have also influenced procurement and contracting behavior. Across Europe, Middle East & Africa, heterogeneous regulatory pathways and payer models have led manufacturers to pursue localized evidence generation and adaptive pricing arrangements to secure formulary inclusion and maintain profitability.

In the Asia-Pacific region, rapid investment in diagnostic infrastructure, growing clinical trial activity, and increasing demand from aging populations have accelerated uptake of next-generation therapeutics, while a focus on manufacturing scale and cost optimization has made the region central to global supply networks. Cross-region collaboration, such as multinational clinical programs and harmonized regulatory submissions, has become more common as developers seek to shorten time-to-market and align safety monitoring across jurisdictions. Variations in healthcare infrastructure and provider distribution also affect where procedural capacity is concentrated, often requiring differentiated commercial and training strategies for specialty centers versus community clinics.

Understanding these regional nuances is critical for designing phased market entry plans, aligning regulatory dossiers with local evidence needs, and developing channel strategies that reflect payer expectations and provider capabilities within each geography.

Strategic corporate behaviors and partnership models shaping therapeutic leadership, delivery innovations, and integrated offerings in the AMD ecosystem

Corporate strategy in the age-related macular degeneration ecosystem is characterized by a mix of portfolio diversification, targeted partnerships, and investments in advanced manufacturing and data capabilities. Established biopharmaceutical sponsors maintain leadership through iterative improvements to licensed anti-VEGF agents and by sponsoring real-world evidence studies to support label expansions and dosing innovations. Simultaneously, companies with niche capabilities in sustained-delivery systems and ocular devices are leveraging strategic alliances to combine delivery platforms with established biologics, creating differentiated offerings that address clinician and patient demand for reduced treatment burden.

Across the competitive landscape, alliances between therapeutic developers, contract manufacturers, and diagnostic vendors have increased, reflecting a recognition that integrated solutions-combining therapy, monitoring, and adherence tools-provide stronger commercial value propositions. Investment activity has favored firms that can demonstrate scalable aseptic manufacturing, robust cold-chain logistics, and regulatory experience in ophthalmic modalities. Additionally, firms pursuing novel mechanisms for geographic atrophy and complement inhibition have attracted attention from investors and partners, underscoring the broader appetite for first-in-class interventions within dry AMD.

Companies that prioritize interoperable data strategies, regulatory planning for global submissions, and flexible commercial models for diverse payer environments are better positioned to capture opportunities. At the same time, market entrants must navigate pricing scrutiny and evidentiary expectations, making strategic collaborations and selective evidence generation crucial to commercial success.

Practical and prioritized strategic actions executives should implement to strengthen clinical value, supply resilience, market access, and commercial differentiation

Industry leaders should pursue a set of pragmatic actions to align clinical value with commercial sustainability and operational resilience. First, prioritize development of durable delivery mechanisms and combination approaches that demonstrably reduce treatment frequency while preserving or enhancing long-term visual outcomes; evidence packages should emphasize patient-centric endpoints and health system resource utilization. Second, strengthen supply chain flexibility by qualifying multiple manufacturing partners across geographies and by investing in inventory analytics that reduce lead-time risk while controlling working capital demands.

Third, implement differentiated market access strategies that tailor evidence generation to regional payer expectations and to the specific needs of clinics, hospitals, and specialty centers. This includes negotiation-ready value propositions that reflect real-world treatment pathways and potential savings from reduced visit burden. Fourth, embed digital and diagnostic partnerships into commercial plans to support remote monitoring, adherence programs, and outcome tracking, thereby improving post-launch data collection and enabling outcome-based contracting where feasible. Fifth, foster cross-functional alignment between regulatory, clinical, and commercial teams to streamline global submissions and coordinate post-approval safety monitoring, which will accelerate adoption while maintaining compliance.

Taken together, these actions reduce operational exposure, enhance provider and patient value, and create defensible differentiation in a competitive therapeutic landscape. Executives should sequence investments to balance near-term revenue protection with mid- to long-term capability building that supports sustained leadership.

A robust mixed-methods research framework integrating primary stakeholder interviews, secondary regulatory and clinical evidence, and scenario validation for actionable intelligence

The research approach combined primary qualitative inquiry with comprehensive secondary evidence review to ensure robustness and practical relevance. Primary research included structured interviews with ophthalmologists, procurement leads in hospitals and specialty centers, senior commercial executives, and clinical trial investigators to capture frontline perspectives on treatment adoption, operational constraints, and payer interactions. Secondary sources encompassed peer-reviewed clinical literature, regulatory approval documents, clinical trial registries, and public filings to validate therapeutic profiles, indications, and safety data.

Data synthesis involved cross-validation of interview insights with published evidence and regulatory summaries, supplemented by scenario analysis to explore operational and policy contingencies such as tariff changes or shifts in reimbursement. Segmentation frameworks were developed by mapping therapeutic modalities, drug classes, disease subtypes, end-user settings, and distribution channels to clinical workflows and procurement pathways. Quality assurance measures included reconciliation of conflicting sources, iterative expert review, and transparent documentation of assumptions and inclusion criteria.

Limitations of the methodology include variability in regional reporting standards and the evolving nature of clinical trial outcomes, which necessitates ongoing monitoring of late-stage data. Nonetheless, the triangulated approach provides a reliable foundation for strategic decision-making by integrating real-world clinician perspectives with rigorous secondary evidence and disciplined analytical techniques.

Concluding synthesis linking clinical innovation, operational preparedness, and strategic imperatives required to realize improved outcomes in age-related macular degeneration

In sum, the age-related macular degeneration landscape is at an inflection point where therapeutic innovation, delivery technologies, and systemic pressures intersect to reshape care paradigms. Advances that reduce treatment frequency or address unmet needs in dry AMD offer meaningful clinical promise, but their realization depends on coordinated evidence generation, adaptive commercial models, and resilient supply chains. Stakeholders who proactively adapt procurement practices, invest in manufacturing agility, and align evidence strategies with payer expectations will be better equipped to translate scientific breakthroughs into sustainable clinical and commercial value.

Operationally, the capacity to integrate diagnostics, digital monitoring, and adherence solutions into product offerings will influence adoption trajectories and payer receptivity. Strategically, selective partnerships and targeted regional approaches enable sponsors to balance the demands of regulatory heterogeneity and localized payer systems. As the landscape continues to evolve, ongoing vigilance, flexible planning, and a focus on measurable patient benefit will be essential to converting innovation into improved outcomes across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Age-related Macular Degeneration Market, by Disease Type

  • 8.1. Wet AMD
  • 8.2. Dry AMD

9. Age-related Macular Degeneration Market, by Treatment Modality

  • 9.1. Pharmacotherapy
    • 9.1.1. Anti-VEGF Agents
      • 9.1.1.1. Aflibercept
      • 9.1.1.2. Ranibizumab
      • 9.1.1.3. Bevacizumab
      • 9.1.1.4. Brolucizumab
    • 9.1.2. Complement Inhibitors
      • 9.1.2.1. Pegcetacoplan
      • 9.1.2.2. Avacincaptad Pegol
    • 9.1.3. Tyrosine Kinase Inhibitors
    • 9.1.4. Integrin Inhibitors
    • 9.1.5. Nutritional Supplementation
  • 9.2. Gene Therapy
  • 9.3. Photodynamic Therapy
  • 9.4. Radiotherapy
  • 9.5. Vision Rehabilitation & Assistive Devices

10. Age-related Macular Degeneration Market, by Baseline Visual Acuity

  • 10.1. >= 20/40
  • 10.2. 20/50 To 20/200
  • 10.3. < 20/200

11. Age-related Macular Degeneration Market, by Route of Administration

  • 11.1. Intravitreal Injection
  • 11.2. Oral Administration
  • 11.3. Topical Ophthalmic

12. Age-related Macular Degeneration Market, by Distribution Channel

  • 12.1. Online Pharmacy
  • 12.2. Offline Pharmacy

13. Age-related Macular Degeneration Market, by End User

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Specialty Ophthalmic Centers
  • 13.4. Home Care Settings

14. Age-related Macular Degeneration Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Age-related Macular Degeneration Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Age-related Macular Degeneration Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Age-related Macular Degeneration Market

18. China Age-related Macular Degeneration Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Apellis Pharmaceuticals, Inc.
  • 19.8. Astellas Pharma Inc.
  • 19.9. F. Hoffmann-La Roche AG
  • 19.10. Novartis AG
  • 19.11. Outlook Therapeutics, Inc.
  • 19.12. Regeneron Pharmaceuticals, Inc.
  • 19.13. Samsung Bioepis Co., Ltd.
  • 19.14. Sandoz Group AG
  • 19.15. STADA Arzneimittel AG
  • 19.16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AMD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AMD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AMD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AMD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AMD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AMD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PEGCETACOPLAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PEGCETACOPLAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AVACINCAPTAD PEGOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AVACINCAPTAD PEGOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AVACINCAPTAD PEGOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VISION REHABILITATION & ASSISTIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VISION REHABILITATION & ASSISTIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VISION REHABILITATION & ASSISTIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY >= 20/40, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY >= 20/40, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY >= 20/40, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY 20/50 TO 20/200, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY 20/50 TO 20/200, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY 20/50 TO 20/200, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY < 20/200, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY < 20/200, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY < 20/200, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TOPICAL OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TOPICAL OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TOPICAL OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 226. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)